Skip to main content
Premium Trial:

Request an Annual Quote

Denmark s Exiqon A/S Takes $3 Million Funding

NEW YORK, February 12 -- Exiqon A/S of Copenhagen, Denmark, today announced a fourth-round funding of $3 million.

 

The company said the funding follows a restructuring and layoffs. Details were not available. Investors in the round include Danske Bank, LD, Nobel Group, Scandinavian Life Sciences Venture, and Teknoinvest, the company said. Exiqon will seek an additional $1.5 million in capital, the company said in a statement.

 

The company is commercializing the synthesis and applications of LNA, a novel high-affinity DNA analog with the promise of creating specificity and affinity for conventional DNA-based techniques, the company said.

 

The firm is hoping that the funding, and the restructuring, will help it bridge the gap between development and commercialization, or "until sufficient license revenues are secured by first quarter 2004," the company said in a statement.

 

The Scan

Study Reveals New Details About Genetics of Major Cause of Female Infertility

Researchers in Nature Medicine conducted a whole-exome sequencing study of mote than a thousand patients with premature ovarian insufficiency.

Circulating Tumor DNA Shows Potential as Biomarker in Rare Childhood Cancer

A study in the Journal of Clinical Oncology has found that circulating tumor DNA levels in rhabdomyosarcoma may serve as a biomarker for prognosis.

Study Recommends Cancer Screening for Dogs Beginning Age Seven, Depending on Breed

PetDx researchers report in PLOS One that annual cancer screening for dogs should begin by age seven.

White-Tailed Deer Harbor SARS-CoV-2 Variants No Longer Infecting Humans, Study Finds

A new study in PNAS has found that white-tailed deer could act as a reservoir of SARS-CoV-2 variants no longer found among humans.